Dihexa (PNB-0408)
PNB-0408 · Angiotensin-IV analog
An experimental peptidomimetic studied for synaptogenic and neuroplastic effects in preclinical models.
Mechanism
Proposed HGF/c-Met signaling modulation
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Human evidence is absent, limited or not confirmatory
Anecdotal schedules are excluded because frequency of online repetition does not establish identity, safety, or a clinically meaningful dose.
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Common low oral schedule | 5–10 mg | 5–10 mg/day | Once daily | Morning | Oral | Community-reported |
| Community subcutaneous range | 1–5 mg | 1–5 mg/day | Once daily | Morning | Subcutaneous | Community-reported |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
At this concentration, 5 mg equals 1.00 mL (100 U-100 units), an unusually large subcutaneous volume. Injectable Dihexa remains experimental and community-reported rather than clinically validated.
Community reference: Path to Peptides community guideImportant: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
Cycle Structure
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 1–5 mg | Once daily | 7–35 mg/week |
Peptide Vials
| Cycle | Total compound | Vials needed | How long one vial lasts |
|---|---|---|---|
| 4 weeks | 28–140 mg | 3–14 × 10 mg | 2–10 administrations |
| 8 weeks | 56–280 mg | 6–28 × 10 mg | 2–10 administrations |
| 12 weeks | 84–420 mg | 9–42 × 10 mg | 2–10 administrations |
Bacteriostatic Water
| Cycle | Total water used | 10 mL bottles needed |
|---|---|---|
| 4 weeks | 6–28 mL | 1–3 × 10 mL |
| 8 weeks | 12–56 mL | 2–6 × 10 mL |
| 12 weeks | 18–84 mL | 2–9 × 10 mL |
Insulin Syringes (U-100)
| Cycle | Administrations | Syringes needed |
|---|---|---|
| 4 weeks | 28 | 28 |
| 8 weeks | 56 | 56 |
| 12 weeks | 84 | 84 |
Ranges reflect the low and high ends of the displayed community schedule. Vials and 10 mL water bottles are rounded up; one new U-100 syringe is counted per subcutaneous administration.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
There is no established therapeutic human exposure, efficacy or long-term safety profile.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.